Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Liver Transplantation | Research article

Potential utility of a multi-component coagulation factor panel to calculate MELD scores and assess the risk of portal vein thrombosis in chronic liver disease

Authors: Clayton S. Lewis, Khurram Bari, Changchun Xie, Kenneth E. Sherman, Marc Vasse, Patrick Van Dreden, Vladimir Y. Bogdanov

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Current quantitative approaches to assess chronic liver disease (CLD) severity have limitations. Further, portal vein thrombosis (PVT) pre-liver transplant (LT) is a major contributor to morbidity in CLD; the means of detecting and/or predicting PVT are limited. We sought to explore whether plasma coagulation factor activity levels can serve as a substitute for prothrombin time/international normalized ratio (PT/INR) in the Model for End-stage Liver Disease (MELD), and/or help assess the risk of PVT.

Methods

Plasma activity levels of Factor V (FV), Factor VIII (FVIII), Protein C (PC), and Protein S (PS) and the concentrations of D-dimer, sP-selectin, and asTF were assessed in two cohorts of CLD patients (ambulatory, n = 42; LT, n = 43).

Results

FV and PC activity levels strongly correlated with MELD scores, which enabled the development of a novel scoring system based on multiple linear regressions of the correlations of FV and PC activity with MELD-Na that substitutes PT/INR. Six-month and 1-year follow-up revealed that our novel approach was non-inferior to MELD-Na at predicting mortality. A significant inverse correlation between FVIII activity levels and PVT was found in the LT cohort (p = 0.010); FV and PS activity levels were in-trend (p = 0.069, p = 0.064). We developed a logistic regression-based compensation score to identify patients at risk of PVT.

Conclusions

We demonstrate that FV and PC activity levels may be used to replace PT/INR in MELD scoring. We also show the potential of using the combination of FV, FVIII, and PS activity levels to assess the risk of PVT in CLD.
Literature
1.
go back to reference National Center for Health Statistics. Health, United States, 2017: with special feature on mortality. 2018. p. 29, 61. National Center for Health Statistics. Health, United States, 2017: with special feature on mortality. 2018. p. 29, 61.
3.
go back to reference Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou P-E, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet J-C, Valla D-C. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61:660–7. https://doi.org/10.1002/HEP.27546.CrossRefPubMed Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou P-E, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet J-C, Valla D-C. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61:660–7. https://​doi.​org/​10.​1002/​HEP.​27546.CrossRefPubMed
5.
go back to reference Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;73:366–413. https://doi.org/10.1002/HEP.31646.CrossRefPubMed Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;73:366–413. https://​doi.​org/​10.​1002/​HEP.​31646.CrossRefPubMed
8.
go back to reference Biland L, Duckert F, Prisender S, Nyman D. Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemost. 1978;39:646–56.CrossRefPubMed Biland L, Duckert F, Prisender S, Nyman D. Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemost. 1978;39:646–56.CrossRefPubMed
12.
go back to reference Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A. von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018;47:980–8. https://doi.org/10.1111/apt.14522.CrossRefPubMed Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A. von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018;47:980–8. https://​doi.​org/​10.​1111/​apt.​14522.CrossRefPubMed
20.
29.
go back to reference Turon F, Driever EG, Baiges A, Cerda E, García-Criado Á, Gilabert R, Bru C, Berzigotti A, Nuñez I, Orts L, Reverter JC, Magaz M, Camprecios G, Olivas P, Betancourt-Sanchez F, Perez-Campuzano V, Blasi A, Seijo S, Reverter E, Bosch J, et al. Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol. 2021;75:1367–76. https://doi.org/10.1016/J.JHEP.2021.07.020.CrossRefPubMed Turon F, Driever EG, Baiges A, Cerda E, García-Criado Á, Gilabert R, Bru C, Berzigotti A, Nuñez I, Orts L, Reverter JC, Magaz M, Camprecios G, Olivas P, Betancourt-Sanchez F, Perez-Campuzano V, Blasi A, Seijo S, Reverter E, Bosch J, et al. Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol. 2021;75:1367–76. https://​doi.​org/​10.​1016/​J.​JHEP.​2021.​07.​020.CrossRefPubMed
32.
go back to reference Unruh D, Sagin F, Adam M, Van Dreden P, Woodhams BJ, Hart K, Lindsell CJ, Ahmad SA, Bogdanov VY. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype. Ann Surg Oncol. 2015;22:1206–11. https://doi.org/10.1245/s10434-015-4592-2.CrossRef Unruh D, Sagin F, Adam M, Van Dreden P, Woodhams BJ, Hart K, Lindsell CJ, Ahmad SA, Bogdanov VY. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype. Ann Surg Oncol. 2015;22:1206–11. https://​doi.​org/​10.​1245/​s10434-015-4592-2.CrossRef
35.
go back to reference Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R, Colombani PM, Cottingham PC, Dunn SP, Fung JJ, Hanto DW, McDiarmid SV, Rabkin JM, Teperman LW, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6. https://doi.org/10.1053/GAST.2003.50016.CrossRefPubMed Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R, Colombani PM, Cottingham PC, Dunn SP, Fung JJ, Hanto DW, McDiarmid SV, Rabkin JM, Teperman LW, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6. https://​doi.​org/​10.​1053/​GAST.​2003.​50016.CrossRefPubMed
38.
go back to reference Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253-1260.e4. https://doi.org/10.1053/J.GASTRO.2012.07.018.CrossRefPubMed Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253-1260.e4. https://​doi.​org/​10.​1053/​J.​GASTRO.​2012.​07.​018.CrossRefPubMed
Metadata
Title
Potential utility of a multi-component coagulation factor panel to calculate MELD scores and assess the risk of portal vein thrombosis in chronic liver disease
Authors
Clayton S. Lewis
Khurram Bari
Changchun Xie
Kenneth E. Sherman
Marc Vasse
Patrick Van Dreden
Vladimir Y. Bogdanov
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02695-6

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.